Selecta Biosciences (SELB) Cut to “Hold” at Zacks Investment Research

Selecta Biosciences (NASDAQ:SELB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “

Other equities analysts have also issued reports about the company. BidaskClub lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 27th. Mizuho reiterated a “buy” rating and issued a $30.00 price objective on shares of Selecta Biosciences in a research note on Wednesday, October 17th. Stifel Nicolaus reiterated a “buy” rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. UBS Group set a $6.00 price objective on Selecta Biosciences and gave the stock a “hold” rating in a research note on Friday, November 9th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $23.21.

Selecta Biosciences stock opened at $2.39 on Thursday. The stock has a market capitalization of $59.45 million, a PE ratio of -0.75 and a beta of 2.62. Selecta Biosciences has a 52 week low of $2.28 and a 52 week high of $16.55.

Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08. On average, research analysts predict that Selecta Biosciences will post -2.92 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in Selecta Biosciences during the third quarter valued at about $196,000. MetLife Investment Advisors LLC bought a new position in Selecta Biosciences during the third quarter valued at about $225,000. Rhumbline Advisers increased its stake in Selecta Biosciences by 43.7% during the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after acquiring an additional 5,103 shares during the period. Virtu Financial LLC bought a new position in Selecta Biosciences during the third quarter valued at about $363,000. Finally, Marshall Wace LLP bought a new position in Selecta Biosciences during the third quarter valued at about $396,000. Hedge funds and other institutional investors own 51.04% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Read More: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply